Merck & Co., US pharmaceutical company (MSD outside the US and Canada)
Merck & Co., US pharmaceutical company (MSD outside the US and Canada)
Phase 3 data for Merck & Co. and Moderna’s personalized mRNA cancer vaccine intismeran autogene were presented at ESMO’s Presidential Symposium in Madrid, days after a pre-conference data leak.
The FDA on October 14 expanded Anktiva (nogapendekin alfa inbakicept-pmln) to adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, as ImmunityBio works through a March warning letter over its promotion …
The FDA approved belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma after prior immunotherapy, adding a second approved indication for belzutifan in 2026 and expanding Merck …
The FDA has approved a label update for sotatercept (Winrevair) incorporating HYPERION trial data, extending the drug’s clinical evidence base to recently diagnosed pulmonary arterial hypertension patients on background therapy.
ANS has added a PARP inhibitor for BRCA1/2-positive metastatic castration-resistant prostate cancer to Brazil’s mandatory private insurance coverage list, effective July 1, 2026, following public consultation.
Law 15.385/2026 mandates SUS incorporation of CONITEC-approved oncology drugs while a Fiocruz-MSD partnership delivers 100% domestically produced pembrolizumab, reducing Brazil’s import dependence for a flagship immunotherapy.
ANVISA has approved serplulimab as the only anti-PD-1 authorized in Brazil for extensive-stage small cell lung cancer, giving Abbott a regulatory head start before larger checkpoint inhibitor rivals.
You must be logged in to post a comment.